NCT00436644 is a Phase 2 clinical trial of Lapatinib in Ovarian Cancer, sponsored by Mayo Clinic.

Who is sponsoring NCT00436644?

NCT00436644 is sponsored by Mayo Clinic.

What drugs are being tested in NCT00436644?

Interventions in NCT00436644: Lapatinib, Topotecan.

What condition does NCT00436644 study?

NCT00436644 studies Ovarian Cancer, Peritoneal Cavity Cancer.

Is NCT00436644 still recruiting?

NCT00436644 is currently completed. Last updated 20 March 2014.

Are results published for NCT00436644?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-03-20 · How we verify

NCT00436644

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma

Completed Phase 2 Results posted Last updated 20 March 2014

What this trial tests

Phase 2 trial testing Lapatinib in Ovarian Cancer in 18 participants. Completed in 1 November 2012.

Timeline

1 March 2007

Primary endpoint
1 March 2009

1 November 2012

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 March 2007
Primary completion	1 March 2009
Estimated completion	1 November 2012
Sites	3 locations across United States

Drugs / interventions tested

Lapatinib (LAPATINIB) — full drug profile →
Topotecan (topotecan) — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Peritoneal Cavity Cancer — all drugs for Peritoneal Cavity Cancer →

Sponsor

Mayo Clinic

Who can join

18 and older, female only, with Ovarian Cancer or Peritoneal Cavity Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response Rate (Complete Response (CR) or Partial Response (PR))
Time frame: Two consecutive evaluations at least 4 weeks apart
Measurable disease patients: measureable disease is defined as at least one lesion whose longest diameter \>= 2cm with conventional techniques or \>=1cm with spiral CT * Confirmed tumor response (complete and partial) as measured by RECIST(Response Evaluation Criteria In Solid Tumors) criteria on 2 consecutive evaluations at least 4 weeks apart. * Confirmed tumor response is at least a 30% decrea

Sponsor's own description

RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with topotecan may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving lapatinib together with topotecan works in treating patients with ovarian epithelial cancer or primary peritoneal cancer that did not respond to cisplatin or carboplatin.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
Hypoxic Microenvironment and Metastatic Bone Disease.
Hiraga T. · · 2018 · cited 50× · PMID 30423905 · DOI 10.3390/ijms19113523
Ovarian cancer: opportunity for targeted therapy.
Tagawa T, Morgan R, Yen Y, Mortimer J. · · 2012 · cited 16× · PMID 22235203 · DOI 10.1155/2012/682480
Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
Wei Y, Erfani S, Schweer D, de Gouvea R, et al · · 2023 · cited 15× · PMID 36911068 · DOI 10.1016/j.omto.2023.02.006
Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview.
Baglini E, Chiaverini L, Tolbatov I, Taliani S, et al · · 2024 · cited 2× · PMID 37930483 · DOI 10.1007/s10534-023-00547-0

Verify or expand the search:

Other trials of Lapatinib

Trials testing the same drug.

NCT03784014 — Molecular Profiling of Advanced Soft-tissue Sarcomas · Phase 3 · active not recruiting
NCT03523585 — DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] · Phase 3 · completed
NCT04185649 — The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer · Phase 3 · unknown
NCT03500380 — A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without L · Phase 2, PHASE3 · unknown
NCT03084939 — Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2 · Phase 3 · completed

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00436644 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 20 March 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00436644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing